| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study.
|
Lancet
|
2004
|
42.12
|
|
2
|
Apixaban versus warfarin in patients with atrial fibrillation.
|
N Engl J Med
|
2011
|
23.50
|
|
3
|
Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial.
|
Lancet
|
2008
|
13.15
|
|
4
|
Apixaban in patients with atrial fibrillation.
|
N Engl J Med
|
2011
|
9.97
|
|
5
|
Effect of ramipril on the incidence of diabetes.
|
N Engl J Med
|
2006
|
9.69
|
|
6
|
Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial.
|
Lancet
|
2011
|
8.49
|
|
7
|
Randomized trial of primary PCI with or without routine manual thrombectomy.
|
N Engl J Med
|
2015
|
7.83
|
|
8
|
Urinary sodium and potassium excretion, mortality, and cardiovascular events.
|
N Engl J Med
|
2014
|
7.54
|
|
9
|
A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry.
|
JAMA
|
2004
|
7.32
|
|
10
|
Predictors of hospital mortality in the global registry of acute coronary events.
|
Arch Intern Med
|
2003
|
7.25
|
|
11
|
Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey.
|
Lancet
|
2011
|
5.95
|
|
12
|
Randomized Trial of Benznidazole for Chronic Chagas' Cardiomyopathy.
|
N Engl J Med
|
2015
|
5.31
|
|
13
|
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
|
Lancet
|
2010
|
5.30
|
|
14
|
Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries.
|
JAMA
|
2013
|
5.19
|
|
15
|
Practice variation and missed opportunities for reperfusion in ST-segment-elevation myocardial infarction: findings from the Global Registry of Acute Coronary Events (GRACE).
|
Lancet
|
2002
|
4.99
|
|
16
|
Cardiovascular risk and events in 17 low-, middle-, and high-income countries.
|
N Engl J Med
|
2014
|
4.88
|
|
17
|
Association of urinary sodium and potassium excretion with blood pressure.
|
N Engl J Med
|
2014
|
4.86
|
|
18
|
Early versus delayed invasive intervention in acute coronary syndromes.
|
N Engl J Med
|
2009
|
4.83
|
|
19
|
Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial.
|
Circulation
|
2012
|
4.33
|
|
20
|
Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE).
|
BMJ
|
2006
|
4.18
|
|
21
|
Validation and comparison of three formulae to estimate sodium and potassium excretion from a single morning fasting urine compared to 24-h measures in 11 countries.
|
J Hypertens
|
2014
|
3.66
|
|
22
|
Glucose-insulin-potassium therapy in patients with ST-segment elevation myocardial infarction.
|
JAMA
|
2007
|
3.09
|
|
23
|
How strong is the evidence for the use of perioperative beta blockers in non-cardiac surgery? Systematic review and meta-analysis of randomised controlled trials.
|
BMJ
|
2005
|
2.97
|
|
24
|
Darapladib for preventing ischemic events in stable coronary heart disease.
|
N Engl J Med
|
2014
|
2.90
|
|
25
|
Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial.
|
JAMA
|
2004
|
2.89
|
|
26
|
Extent of, and factors associated with, delay to hospital presentation in patients with acute coronary disease (the GRACE registry).
|
Am J Cardiol
|
2002
|
2.82
|
|
27
|
Characteristics and short-term prognosis of perioperative myocardial infarction in patients undergoing noncardiac surgery: a cohort study.
|
Ann Intern Med
|
2011
|
2.80
|
|
28
|
Specific barriers to the conduct of randomized trials.
|
Clin Trials
|
2008
|
2.68
|
|
29
|
The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study.
|
Circulation
|
2013
|
2.64
|
|
30
|
Adherence to evidence-based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study.
|
Am J Med
|
2004
|
2.53
|
|
31
|
Brazilian Sepsis Epidemiological Study (BASES study).
|
Crit Care
|
2004
|
2.49
|
|
32
|
Risk factors for acute myocardial infarction in Latin America: the INTERHEART Latin American study.
|
Circulation
|
2007
|
2.24
|
|
33
|
Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT).
|
Am Heart J
|
2008
|
1.99
|
|
34
|
Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study.
|
Circulation
|
2003
|
1.98
|
|
35
|
Management and 6-month outcomes in elderly and very elderly patients with high-risk non-ST-elevation acute coronary syndromes: The Global Registry of Acute Coronary Events.
|
Eur Heart J
|
2008
|
1.86
|
|
36
|
Effect of telmisartan on renal outcomes: a randomized trial.
|
Ann Intern Med
|
2009
|
1.85
|
|
37
|
Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial.
|
JAMA
|
2010
|
1.66
|
|
38
|
Unprotected left main revascularization in patients with acute coronary syndromes.
|
Eur Heart J
|
2009
|
1.66
|
|
39
|
Two-year outcomes in patients admitted with non-ST elevation acute coronary syndrome: results of the OASIS registry 1 and 2.
|
Indian Heart J
|
2005
|
1.59
|
|
40
|
The BENEFIT trial: testing the hypothesis that trypanocidal therapy is beneficial for patients with chronic Chagas heart disease.
|
Mem Inst Oswaldo Cruz
|
2009
|
1.54
|
|
41
|
Initial clinical results using intracardiac electrogram monitoring to detect and alert patients during coronary plaque rupture and ischemia.
|
J Am Coll Cardiol
|
2010
|
1.54
|
|
42
|
Has the frequency of bleeding changed over time for patients presenting with an acute coronary syndrome? The global registry of acute coronary events.
|
Eur Heart J
|
2009
|
1.53
|
|
43
|
Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study.
|
Eur Heart J
|
2008
|
1.52
|
|
44
|
Design and rationale of the radial versus femoral access for coronary intervention (RIVAL) trial: a randomized comparison of radial versus femoral access for coronary angiography or intervention in patients with acute coronary syndromes.
|
Am Heart J
|
2011
|
1.48
|
|
45
|
Estimating modifiable coronary heart disease risk in multiple regions of the world: the INTERHEART Modifiable Risk Score.
|
Eur Heart J
|
2010
|
1.39
|
|
46
|
Variations in cause and management of atrial fibrillation in a prospective registry of 15,400 emergency department patients in 46 countries: the RE-LY Atrial Fibrillation Registry.
|
Circulation
|
2014
|
1.30
|
|
47
|
Global patterns of use of antithrombotic and antiplatelet therapies in patients with acute coronary syndromes: insights from the Global Registry of Acute Coronary Events (GRACE).
|
Am Heart J
|
2003
|
1.29
|
|
48
|
Relationship between healthy diet and risk of cardiovascular disease among patients on drug therapies for secondary prevention: a prospective cohort study of 31 546 high-risk individuals from 40 countries.
|
Circulation
|
2012
|
1.24
|
|
49
|
Access to catheterisation facilities in patients admitted with acute coronary syndrome: multinational registry study.
|
BMJ
|
2005
|
1.20
|
|
50
|
Effectiveness of primary percutaneous coronary intervention compared with that of thrombolytic therapy in elderly patients with acute myocardial infarction.
|
Am Heart J
|
2004
|
1.19
|
|
51
|
Environmental Profile of a Community's Health (EPOCH): an instrument to measure environmental determinants of cardiovascular health in five countries.
|
PLoS One
|
2010
|
1.18
|
|
52
|
Risk factors for myocardial infarction in Brazil.
|
Am Heart J
|
2003
|
1.11
|
|
53
|
Association of elevated fasting glucose with increased short-term and 6-month mortality in ST-segment elevation and non-ST-segment elevation acute coronary syndromes: the Global Registry of Acute Coronary Events.
|
Arch Intern Med
|
2009
|
0.97
|
|
54
|
Acute coronary syndrome behavior: results of a Brazilian registry.
|
Arq Bras Cardiol
|
2013
|
0.95
|
|
55
|
Prospective Urban Rural Epidemiology (PURE) study: Baseline characteristics of the household sample and comparative analyses with national data in 17 countries.
|
Am Heart J
|
2013
|
0.95
|
|
56
|
Mortality following placement of drug-eluting and bare-metal stents for ST-segment elevation acute myocardial infarction in the Global Registry of Acute Coronary Events.
|
Eur Heart J
|
2009
|
0.93
|
|
57
|
Impact of prior peripheral arterial disease and stroke on outcomes of acute coronary syndromes and effect of evidence-based therapies (from the Global Registry of Acute Coronary Events).
|
Am J Cardiol
|
2007
|
0.93
|
|
58
|
The association between ownership of common household devices and obesity and diabetes in high, middle and low income countries.
|
CMAJ
|
2014
|
0.92
|
|
59
|
Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trials.
|
Circulation
|
2008
|
0.90
|
|
60
|
Environmental Profile of a Community's Health (EPOCH): an ecometric assessment of measures of the community environment based on individual perception.
|
PLoS One
|
2012
|
0.86
|
|
61
|
Association of peripheral artery disease with treatment and outcomes in acute coronary syndromes. The Global Registry of Acute Coronary Events (GRACE).
|
Am Heart J
|
2006
|
0.86
|
|
62
|
Influenza vaccination and major adverse vascular events in high-risk patients.
|
Circulation
|
2012
|
0.86
|
|
63
|
Glucose levels compared with diabetes history in the risk assessment of patients with acute myocardial infarction.
|
Am Heart J
|
2009
|
0.85
|
|
64
|
Impact of in-hospital revascularization on survival in patients with non-ST-elevation acute coronary syndrome and congestive heart failure.
|
Circulation
|
2008
|
0.82
|
|
65
|
[Electrical cardioversion and myocardial injury: evaluation by new cardiac injury markers].
|
Arq Bras Cardiol
|
2006
|
0.81
|
|
66
|
Predicting coronary artery bypass graft surgery in acute coronary syndromes.
|
EuroIntervention
|
2007
|
0.81
|
|
67
|
Comparison of utilization of statin therapy at hospital discharge and six-month outcomes in patients with an acute coronary syndrome and serum low-density lipoprotein>or=100 mg/dl versus<100 mg/dl.
|
Am J Cardiol
|
2007
|
0.80
|
|
68
|
Management of diabetes mellitus and associated cardiovascular risk factors in Brazil - the Brazilian study on the practice of diabetes care.
|
Diabetol Metab Syndr
|
2013
|
0.77
|
|
69
|
[The impact of diabetes mellitus on the mortality of acute coronary syndromes].
|
Arq Bras Endocrinol Metabol
|
2007
|
0.77
|
|
70
|
Comparison between cardiac troponin I and CK-MB mass in acute coronary syndrome without st elevation.
|
Arq Bras Cardiol
|
2011
|
0.76
|
|
71
|
Benznidazole for Chronic Chagas' Cardiomyopathy.
|
N Engl J Med
|
2016
|
0.76
|
|
72
|
Stenting and glycoprotein IIb/IIIa inhibition in patients with acute myocardial infarction undergoing percutaneous coronary intervention: findings from the global registry of acute coronary events (GRACE).
|
Catheter Cardiovasc Interv
|
2003
|
0.76
|
|
73
|
Interactions between heparins, glycoprotein IIb/IIIa antagonists, and coronary intervention. The Global Registry of Acute Coronary Events (GRACE).
|
Am Heart J
|
2007
|
0.76
|
|
74
|
Cardiovascular prevention in coronary heart disease patients: guidelines implementation in clinical practice.
|
Rev Bras Cir Cardiovasc
|
2013
|
0.76
|
|
75
|
Response to letters regarding article, “Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial”.
|
Circulation
|
2013
|
0.75
|
|
76
|
[Evidence based cardiology. Some necessary clarifications].
|
Arq Bras Cardiol
|
2004
|
0.75
|
|
77
|
[C-reactive protein and cardiovascular disease. Basis of scientific evidence].
|
Arq Bras Cardiol
|
2003
|
0.75
|
|
78
|
[Evidence-based cardiology: where to find evidence].
|
Arq Bras Cardiol
|
2006
|
0.75
|
|
79
|
The cost implications of the use of telmisartan or ramipril in patients at high risk for vascular events: the ONTARGET study.
|
J Med Econ
|
2011
|
0.75
|
|
80
|
Pulmonary artery catheterization in patients with acute coronary syndromes.
|
Am Heart J
|
2009
|
0.75
|
|
81
|
[Hypertension and associated clinical conditions].
|
J Bras Nefrol
|
2010
|
0.75
|
|
82
|
Can an elderly woman's heart be too strong? Increased mortality with high versus normal ejection fraction after an acute coronary syndrome. The Global Registry of Acute Coronary Events.
|
Am Heart J
|
2010
|
0.75
|
|
83
|
Use of proven therapies in non-ST-elevation acute coronary syndromes according to evidence-based risk stratification.
|
Am Heart J
|
2007
|
0.75
|
|
84
|
Risk stratification in the setting of non-ST elevation acute coronary syndromes 1999-2007.
|
Am J Cardiol
|
2011
|
0.75
|